Dhtml Menu Css by v5.7


The nanoemulsion technology, developed at the University of Michigan, was transferred to a Biotech Company, NanoBio Corp, Ann Arbor, MI, for further development of applications and commercialization.


An antibiotic free, nasally applied prophylactic treatment effective against Methicillin-resistant Staphylococcus aureus (MRSA) and Vancomycin-resistant staphylococcus (VRSA) is under preclinical development at NanoBio Corp.  MRSA is especially troublesome in hospital-associated (nosocomial) infections. While less prevalent than MSRA, the appearance of VRSA in hospitals would make the treatment of infected patients much more difficult.  Click here for more about NanoBio Corp.’s development of a prophylactic and why our University of Michigan Devloped nanoemulsion can potentially be a break-through treatment for MRSA and VSRA.



© The Michigan Nanotechnology Institute for Medicine and Biological Sciences (MNIMBS)® 2010
MNIMBS is a registered trademark of The Michigan Nanotechnology Institute for Medicine and Biological Sciences.
MNIMBS logo and graphic designed by Paul D. Trombley, website by Mellon & Associates, LLC
All other company, brand, and product names are or may be trademarks of their respective holders.